Keisuke Aoe

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Presence of<i>Epidermal Growth Factor Receptor</i>Gene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer

Michio Inukai, Shinichi Toyooka, Sachio Ito et al. · Cancer Research · 2006 · 447 citations · Full text

Medicine, Oncology, Pharmacology +13

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila et al. · Proceedings of the National Academy of Sciences · 2012 · 437 citations · Full text

Medicine, Molecular Biology, Oncology +17

Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells

Hiroyuki Tao, Yusuke Mimura, Keisuke Aoe et al. · Lung Cancer · 2011 · 250 citations

Life Sciences, Immunology, Oncology +15